Lilly to Market Groundbreaking Alzheimer's Diagnostic Drug

Eli Lilly & Co. (LLY) has gained the green light to market Tauvid which can be used to identify neurofibrillary tangles formed within brain neurons in people with Alzheimer's Disease.  This groundbreaking method using Eli Lilly & Co.'s (LLY) drug is very significant, as the tau tangles previously lacked any way to identify the Alzheimer's characteristic in living individuals.

Alzheimer's is a medical disease of which I have some knowledge.  Second Renaissance Books, the bookstore set up by Ayn Rand herself, sold a book about the condition which I read that was nearly 250 pages.

Eli Lilly & Co. (LLY) has been working on Alzheimer's Disease for a very long time.  Despite this new diagnostic tool, their still remains no medical treatment for Alzheimer's.  However, Lilly's tau-based diagnosis could become widely used.

I googled Alzheimer's population statistics and found that 10% of Americans age 65 and older have Alzheimer's Disease.  And, 32% of those age 85 and older have Alzheimer's.

Eli Lilly's test to alert families about a relative who is beginning to get Alzheimer's Disease may develop a high demand.  And, when one multiplies that demand by the prevalence in the population of America, and the entire World, Eli Lilly & Co.'s (LLY) diagnostic drug could prove lucrative, indeed.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind